A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment

被引:1
|
作者
Marbury, T. [1 ]
Stonerock, R. [1 ]
Acharya, M. [2 ]
Gonzalez, M. [2 ]
Jiao, J. [2 ]
Breeding, J. [3 ]
Haqq, C. [3 ]
Molina, A. [3 ]
Tran, N. [3 ]
机构
[1] Orlando Clin Res Ctr, Orlando, FL USA
[2] Johnson & Johnson Pharmaceut, Res & Developlment, Raritan, NJ USA
[3] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
关键词
D O I
10.1016/S0959-8049(11)72006-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S501 / S501
页数:1
相关论文
共 50 条
  • [41] Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study
    Chattopadhyay, Niladri
    Riecke, Kai
    Ligges, Sandra
    Zimmermann, Torsten
    Halabi, Atef
    Schultze-Mosgau, Marcus-Hillert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 2011 - 2021
  • [42] Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
    Peveling-Oberhag, Jan
    Zeuzem, Stefan
    Yong, Wei Peng
    Kunz, Tiffany
    Paquet, Thierry
    Bouillaud, Emmanuel
    Urva, Shweta
    Anak, Oezlem
    Sellami, Dalila
    Kobalava, Zhanna
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 215 - 225
  • [43] Effects of Hepatic Impairment on the Pharmacokinetics of Nilotinib: An Open-Label, Single-Dose, Parallel-Group Study
    Yin, Ophelia Q. P.
    Gallagher, Neil
    Tanaka, Chiaki
    Fisher, Deirdre
    Sethuraman, Venkat
    Zhou, Wei
    Lin, Tsu-Han
    Heuman, Douglas
    Schran, Horst
    CLINICAL THERAPEUTICS, 2009, 31 : 2459 - 2469
  • [44] Pharmacokinetics of tropifexor, a potent farnesoid X receptor agonist, are similar in subjects with mild, moderate, and severe hepatic impairment: results from a multi-centre, open-label, single-dose study
    Stringer, Rowan
    Chen, Jin
    Gu, Jessie
    Hackling, Melissa
    Shah, Bharti
    Nidamarthy, Prasanna Kumar
    Prince, William
    Woessner, Ralph
    JOURNAL OF HEPATOLOGY, 2021, 75 : S534 - S535
  • [45] EFFECT OF HEPATIC IMPAIRMENT ON COBIMETINIB PHARMACOKINETICS: AN OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY.
    Templeton, I.
    Kshirsagar, S.
    Deng, Y.
    Choong, N.
    Chang, I.
    Georgescu, I.
    Musib, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S102 - S102
  • [46] PHARMACOKINETICS OF SETMELANOTIDE IN INDIVIDUALS WITH RENAL IMPAIRMENT: RESULTS FROM A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY
    Zacchia, Miriam
    Navarria, Andrea
    Baughman, Sharon
    Roux, Willem
    Malhotra, Sonali
    Yuan, Guojun
    Cetiner, Metin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I1133 - I1133
  • [47] Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
    Wiebe, Sabrina
    Schnell, David
    Kuelzer, Raimund
    Gansser, Dietmar
    Weber, Anne
    Wallenstein, Gudrun
    Halabi, Atef
    Conrad, Anja
    Wind, Sven
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (03) : 461 - 469
  • [48] Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
    Sabrina Wiebe
    David Schnell
    Raimund Külzer
    Dietmar Gansser
    Anne Weber
    Gudrun Wallenstein
    Atef Halabi
    Anja Conrad
    Sven Wind
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 461 - 469
  • [49] An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
    Padhi, Desmond
    Langman, Craig B.
    Fathallah-Shaykh, Sahar
    Warady, Bradley A.
    Salusky, Isidro B.
    Lee, Edward
    Wang, Christine
    Posvar, Edward
    PEDIATRIC NEPHROLOGY, 2012, 27 (10) : 1953 - 1959
  • [50] An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
    Desmond Padhi
    Craig B. Langman
    Sahar Fathallah-Shaykh
    Bradley A. Warady
    Isidro B. Salusky
    Edward Lee
    Christine Wang
    Edward Posvar
    Pediatric Nephrology, 2012, 27 : 1953 - 1959